Article Text

Download PDFPDF
Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination
  1. Omar Fueyo-Rodriguez1,
  2. Benjamin Valente-Acosta1,
  3. Rodolfo Jimenez-Soto1,
  4. Yvette Neme-Yunes1,
  5. Sergio Ignacio Inclán-Alarcón1,
  6. Roxana Trejo-Gonzalez1 and
  7. Miguel Ángel García-Salcido2
  1. 1Centro Medico ABC, Ciudad de México, Mexico
  2. 2Mexico’s National Institute of Public Health, Mexico, Mexico
  1. Correspondence to Dr Benjamin Valente-Acosta; benjamin.valente-acosta1{at}


Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer–BioNTech).

  • COVID-19
  • immunological products and vaccines

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • OF-R and BV-A are joint first authors.

  • Contributors BV-A, OF-R and RJ-S conceived the idea and design of the article. OF-R, RJ-S, YN-Y, SIA, RTG, MAGS and BV-A contributed to the preparation and review of the initial manuscript. BV-A drafted the final work and reviewed it critically. All authors approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.